Search results for "ECK"

showing 10 items of 2091 documents

Polska kultura łowiecka jako niematerialne dziedzictwo kulturowe

2021

Pod koniec średniowiecza kultura łowiecka, czerpiąca z etosu rycerskiego, stała się ważnym składnikiem obyczajowości dworskiej, aby w następnych wiekach wpisać się w życie polskiego ziemiaństwa. Mimo wpływów zwłaszcza niemieckich, zachowała odrębność i narodowy charakter, które powodowały, że w czasach zaborów i II Rzeczypospolitej była jednym z czynników kształtujących świadomość narodową. Jej zasadnicze przejawy niszczono w czasach komunizmu, a mimo to przetrwała i została z sukcesem odbudowana w latach 90. XX w., stanowiąc źródło tożsamości wspólnotowej dla ponad 120 tys. myśliwych oraz członków ich rodzin. Polska kultura łowiecka obejmuje zasady etycznego postępowania względem przyrody,…

huntingtradycjamyśliwyjęzyk łowieckipolowanietraditionhunterlanguage of huntingcultural heritagedziedzictwo kulturoweSantander Art and Culture Law Review
researchProduct

First-Line Treatments for Extensive-Stage Small-Cell Lung Cancer With Immune Checkpoint Inhibitors Plus Chemotherapy: A Network Meta-Analysis and Cos…

2022

BackgroundImmune checkpoint inhibitors (ICIs) plus chemotherapy were unlikely to be considered cost-effective compared with chemotherapy as the first-line treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) in China due to its high costs. However, the cost-effectiveness of the comparison between the regimens of ICIs plus chemotherapy were remained unclear yet. The aim of this study was to evaluate the efficacy and cost-effectiveness of ICIs plus chemotherapy as the first-line treatment for ES-SCLC from the perspective of the Chinese healthcare system.MethodsA network meta-analysis (NMA) was conducted to indirect compare the clinical benefits between the ICIs plus che…

immune checkpoint inhibitorsCancer ResearchOncologyNeoplasms. Tumors. Oncology. Including cancer and carcinogenschemotherapyextensive-stage small-cell lung cancercost-effectivenessfirst-line treatmenthealth care economics and organizationsRC254-282Original ResearchFrontiers in Oncology
researchProduct

PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow c…

2022

Peripheral immune-checkpoint blockade with mAbs to programmed cell death receptor-1 (PD-1) (either nivolumab or pembrolizumab) or PD-Ligand-1 (PD-L1) (atezolizumab, durvalumab, or avelumab) alone or in combination with doublet chemotherapy represents an expanding treatment strategy for metastatic non-small cell lung cancer (mNSCLC) patients. This strategy lays on the capability of these mAbs to rescue tumor-specific cytotoxic T lymphocytes (CTLs) inactivated throughout PD-1 binding to PD-L1/2 in the tumor sites. This inhibitory interactive pathway is a physiological mechanism of prevention against dangerous overreactions and autoimmunity in case of prolonged and/or repeated CTL response to …

immune checkpoint inhibitorsCancer Researchimmune systemNSCLOncologybioinformaticNSLCflow cytometryimmune checkpoint inhibitorNKT; NSCL; bioinformatics; flow cytometry; immune checkpoint inhibitorsNKTbioinformaticsPD1.Frontiers in oncology
researchProduct

Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review

2022

Simple Summary Moving from the achievements of immune checkpoint inhibitors in metastatic lung cancer, the great promise of immunotherapy in resectable early-stage is to make a disease, often lethal until now for frequent post-surgery relapses, more curable. This review focuses on role of immunotherapy in early-stage non-small cell lung cancer. We summarize biological rationale, findings from clinical trials of adjuvant and neoadjuvant immune checkpoint inhibitors, questions about biomarkers and choice of endpoints, aiming to provide up-to-date information useful for clinical decision making. Lung cancer is the leading cause of cancer-related death worldwide. Since prognosis of early-stage …

immune checkpoint inhibitorsCancer Researchlung cancernon-small-cell lung carcinoma (NSCLC)OncologyadjuvantSettore MED/06 - Oncologia Medicaneoadjuvantadjuvant; immune checkpoint inhibitors; immunotherapy; lung cancer; neoadjuvant; non-small-cell lung carcinoma (NSCLC);immune checkpoint inhibitorimmunotherapy
researchProduct

Incidence of mucositis during therapy with PD1-PDL1 type immune checkpoint inhibitors

2020

immune checkpoint inhibitorsmucositiscancer
researchProduct

The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems

2022

Cancer is one of the main causes of disease-related deaths in the world. Although cancer treatment strategies have been improved in recent years, the survival time of cancer patients is still far from satisfied. Cancer immunotherapy, such as Oncolytic virotherapy, Immune checkpoints inhibition, Chimeric antigen receptor T (CAR-T) cell therapy, Chimeric antigen receptor natural killer (CAR-NK) cell therapy and macrophages genomic modification, has emerged as an effective therapeutic strategy for different kinds of cancer. However, many patients do not respond to the cancer immunotherapy which warrants further investigation to optimize this strategy. The clustered regularly interspaced short …

immune checkpoints inhibitionCancer ResearchOncologyoncolytic virusesMini ReviewcancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensimmunotherapyCAR-T therapyCRISPR/Cas9RC254-282Frontiers in Oncology
researchProduct

Classification of current anticancer immunotherapies.

2014

© 2014. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

immunostimulatory cytokinesmedicine.medical_treatmentReviewBioinformaticsDNA-based vaccinesEfficacy0302 clinical medicineCancer immunotherapyNeoplasmspeptide-based vaccines0303 health sciencesPatología//purl.org/becyt/ford/3.1 [https]CANCER3. Good healthMedicina BásicaOncologycheckpoint blockers030220 oncology & carcinogenesisQR180//purl.org/becyt/ford/3 [https]ImmunotherapyCIENCIAS MÉDICAS Y DE LA SALUDmedicine.drug_classInmunologíaadoptive cell transfer; checkpoint blockers; dendritic cell-based interventions; DNA-based vaccines; immunostimulatory cytokines; peptide-based vaccines; oncolytic viruses; Toll-like receptor agonistsMonoclonal antibodydendritic cell-based interventionsToll-like receptor agonistsRC025403 medical and health sciencesImmune systemAntigen[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologymedicineAnimalsHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular Biology[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular Biologyadoptive cell transfer030304 developmental biologyIMMUNOTHERAPIESbusiness.industryCancerImmunotherapymedicine.diseaseR1Oncolytic virusoncolytic virusesImmunologybusinessOncotarget
researchProduct

In-house princips Eiropas Savienības tiesībās

2015

In-house izņēmuma vieta ES tiesības ir neskaidra. Vai princips, kas formāli izriet no publiskā iepirkuma tiesībām ir skatāms gan ES konkurences tiesību, gan valsts atbalsta konspektā? Situāciju vēl vairāk sarežģī in-house izņēmuma attiecības ar citu specifisku ES tiesību nozari - vispārējas tautsaimniecības nozares pakalpojumiem. In-house būtībā atļauj nerīkot publisko iepirkumu situācijā, kad tas būtu normāli jādara, ja tikai pašvaldībai vai iestādei ir iespējas publisko līgumu uzticēt sev piederošam uzņēmumam. Tādā veidā var tikt apiets brīvais tirgus un konkurence kā tāda, kas noteikti nav vēlams pasākums ilgtermiņā. Darbā tika noteikts, regulējuma apjoms, kas attiecas un in-house izņēmu…

in-houseTeckalvispārējas tautsaimniecības nozīmes pakalpojumipubliskais iepirkumsvalsts atbalstsJuridiskā zinātne
researchProduct

Mixed Epidermal Cell Lymphocyte Reaction: HLA-DR+ Cells Exhibit a Greater Immunostimulatory Activity than CD1a+ Cells

1995

Induction and expression of immunity depends upon processing and presentation of antigens to T-cells by bone marrow derived HLA-DR+ antigen presenting cells (APC). In the induction of immunity to cutaneous antigens, the initial stages of this process begin within the skin itself, and both epidermis and dermis contain bone-marrow derived cells that have the capability of processing and presenting antigens. In normal epidermis, HLA-DR expression is believed to be confined to Langerhans cells with Birbeck granules and indeterminate cells without Birbeck granules. In diseased skin, particularly the inflammatory dermatoses, HLA-DR is commonly expressed by keratinocytes and has been related to th…

integumentary systemEpidermis (botany)Birbeck granulesLymphocytemedicine.medical_treatmentBiologymedicine.anatomical_structureCytokineAntigenImmunologyHLA-DRmedicineBone marrowAntigen-presenting cell
researchProduct

Kestävyys- ja teholajiurheilijoiden kuormittuminen ja kuormittumisen seuranta lyhyellä aikavälillä

2018

Nikola-Määttä, Sanna (2018). Kestävyys- ja teholajiurheilijoiden kuormittumisen seuranta lyhyellä aikavälillä. Liikuntatieteellinen tiedekunta, Jyväskylän yliopisto, Liikuntafysiologian Pro-Gradu -tutkielma, 69 s. Kuormittumisen seuranta on oleellinen osa urheilijoiden harjoittelua ja valmennusta. Ylikuormitus on yleisempää yksilölajeissa kuin joukkuelajeissa. Kestävyyslajien edustajilla on todettu olevan suurempi riski sairastua ylikuormitustilaan. Lisäksi ylikuormittumista on enemmän aikuisilla miehillä kuin naisilla, mutta toisaalta nuorilla tyttöurheilijoilla on havaittu enemmän ylikuormittumista kuin poikaurheilijoilla. Tässä Pro gradu -työssä on tarkasteltu Vuokatti-Ruka Urheiluakatem…

intensiteettisykevälivaihtelusykehydrokortisoniRMSSDkuormitusCheckMyLevel
researchProduct